Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.
Type:
Application
Filed:
October 11, 2010
Publication date:
June 30, 2011
Applicant:
Merck & Co., Inc.
Inventors:
Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
Abstract: A dispenser for the delivery of medication includes: a support (9, 10) supporting an array of blister(s) (11) each containing a medication dose, the support (9, 10) having an array of through hole(s) (19, 25) below the blister(s) (11) respectively, an actuating member (13) located above the support (9, 10), the actuating member (13) being movable in translation relative to the support (9, 10), by at least one step, in a determined direction (d) parallel to the support (9, 10), and elements (29, 57) for converting each of the step(s) of translational motion of the actuating member (13) into a pressure exerted on corresponding one(s) of the blister(s) (11) towards the corresponding through hole(s) (19, 25) to expel the corresponding medication dose(s) through the corresponding through hole(s) (19, 25).
Abstract: The invention relates to mononuclear, neutral copper (1) complexes having a bidentate ligand that binds via nitrogen, and two phosphane or arsane ligands, to the use thereof for producing electronic components, and to electronic devices comprising said complexes.
Abstract: Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Type:
Grant
Filed:
November 14, 2006
Date of Patent:
June 28, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Ian M. Bell, Craig A. Stump, Cory R. Theberge, Steven N. Gallicchio, C. Blair Zartman
Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
Type:
Grant
Filed:
February 9, 2010
Date of Patent:
June 28, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
John E. Stelmach, Emma R. Parmee, James R. Tata, Keith G. Rosauer, Ronald M. Kim, Amy R. Bittner, Jiang Chang, Christopher Joseph Sinz
Abstract: Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Type:
Grant
Filed:
April 15, 2010
Date of Patent:
June 28, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Joseph P. Vacca, Linda S. Payne, Richard C. A. Isaacs
Abstract: The present invention is directed to 2,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
Type:
Grant
Filed:
April 20, 2005
Date of Patent:
June 28, 2011
Assignee:
Merck, Sharp & Dohme, Corp.
Inventors:
James C. Barrow, Georgia B. McGaughey, Philippe G. Nantermet, Hemaka A. Rajapakse, Harold G. Selnick, Shaun R. Stauffer, Joseph P. Vacca, Shawn J. Stachel, Craig A. Coburn, Matthew G. Stanton
Abstract: The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
Type:
Grant
Filed:
April 23, 2007
Date of Patent:
June 28, 2011
Assignee:
Merck Frosst Canada Ltd.
Inventors:
Michael Boyd, John Colucci, Zhaoyin Wang
Abstract: Chromenoneindole derivatives of the formula (I), in which R1, R2, R3, R, A and B are as defined in Claim 1, and pharmaceutically usable prodrugs, derivatives, solvates, stereoisomers and salts thereof, exhibit particular actions on the central nervous system, in particular 5-HT reuptake-inhibiting and 5-HTx-agonistic and/or -antagonistic actions. They are distinguished by particularly high bioavailability and particularly high inhibition of 5-HT reuptake.
Type:
Grant
Filed:
March 8, 2004
Date of Patent:
June 28, 2011
Assignee:
Merck Patent GmbH
Inventors:
Kai Schiemann, Henning Böttcher, Timo Heinrich, Günter Hölzemann, Christoph Van Amsterdam, Gerd Bartoszyk, Joachim Leibrock, Christoph Seyfried
Abstract: The invention relates to novel compounds which comprise, as cationic or as anionic component, a pyrimidinecarboxylic acid derivative, in particular a derivative of ectoin or hydroxyectoin, to a process for the preparation thereof, and to the use thereof as ionic liquid or to the use thereof in pharmaceutical, cosmetic and dermatological formulations.
Type:
Application
Filed:
June 19, 2009
Publication date:
June 23, 2011
Applicant:
MERCK PATENT GESELLSCHAFT
Inventors:
Michael Howard Rayner-Branes, Thomas Rudolph, William-Robert Pitner, Jens Eichhorn
Abstract: The invention relates to novel calamitic mesogenic compounds which are especially suitable for use in birefringent films with negative optical dispersion, to novel liquid crystal (LC) formulations and polymer films comprising them, and to the use of the compounds, formulations and films in optical, electrooptical, electronic, semiconducting or luminescent components or devices.
Type:
Application
Filed:
July 16, 2009
Publication date:
June 23, 2011
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
Abstract: The present invention relates to chemical compounds comprising a [Y(CHRa)n—CH(Ra)SO3]? anion, their preparation and application. The chemical compounds are preferably ionic liquids.
Type:
Application
Filed:
May 12, 2009
Publication date:
June 23, 2011
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
Inventors:
Peter Wasserscheid, Natalia Paape, Andreas Boesmann, Peter Schulz
Abstract: An organic light emitting diode (OLED) comprising a substrate, a 1st electrode disposed on the substrate and including at least one lead, a 2nd electrode including at least one lead, an organic light-emitting layer disposed between the 1st electrode and the 2nd electrode, and a conductive layer. At least one of (1) the substrate and the 1st electrode and (2) the 2nd electrode are transparent. The conductive layer is disposed on one of the 1st electrode and the 2nd electrode, and effectively surrounds the light-emitting layer and the other of the 1st electrode and the 2nd electrode.
Type:
Grant
Filed:
March 19, 2007
Date of Patent:
June 21, 2011
Assignee:
Merck Patent GmbH
Inventors:
Thomas A. Frank, Peter Fangyun Hsu, Edgar Boehm, Anton Volker Heinrich
Abstract: Disclosed are dielectrically positive liquid-crystalline media containing a dielectrically positive component, component A, containing one or more dielectrically positive compounds of formula I and optionally a second dielectrically positive component, component B, containing one or more dielectrically positive compounds having a dielectric anisotropy of greater than 3, and optionally a dielectrically neutral component, component C, and to liquid-crystal displays, especially active-matrix displays and in particular TN, OCB, IPS and FFS displays, containing these media.
Type:
Grant
Filed:
April 28, 2010
Date of Patent:
June 21, 2011
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Inventors:
Michael Wittek, Brigitte Schuler, Lars Lietzau
Abstract: The invention relates to 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound.
Type:
Application
Filed:
July 27, 2009
Publication date:
June 16, 2011
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
Inventors:
Soheila Anzali, Francis Contard, Jean Jacques Zeiller
Abstract: The present invention relates to the compounds of the formula (1) and to organic electronic devices in which these compounds are used as matrix material in the emitting layer and/or as hole-transport material and/or as electron-blocking or exciton-blocking material and/or as electron-transport material.
Type:
Application
Filed:
June 19, 2009
Publication date:
June 16, 2011
Applicant:
MERCK PATENT GMBH
Inventors:
Philipp Stoessel, Holger Heil, Dominik Joosten, Christof Pflumm, Anja Gerhard, Arne Buesing, Joachim Kaiser
Abstract: The present invention relates to organic electroluminescence devices containing metal complexes having the formula (1) and metal complexes for use in organic electroluminescence devices.
Abstract: The invention relates to a liquid-crystalline medium containing one or more compounds of the formula I and one or more compounds selected from the group of the compounds of the formula IA to IE in which R0, R1, R2, X1, X2, A1, Z1, m, p, q, v have the meanings indicated in claim 1, and to the use thereof in electro-optical liquid-crystal displays.
Type:
Application
Filed:
July 13, 2009
Publication date:
June 16, 2011
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG
Inventors:
Mingchou Wu, Martin (Kelun) Shu, Carol (Yi-Hsuan) Lin, Mark Verrall
Abstract: The invention relates to complexes of certain flavonoid derivatives, of the formula I compositions which comprise such derivatives, corresponding processes for the preparation of the flavonoid derivatives or of compositions comprising same, and the use thereof, in particular for the care, preservation or improvement of the general state of the skin or hair. Formula (1), in which Z1 to Z4 and Z6 to Z10 each, independently of one another, denote H, OH, CH3COO, alkoxy, hydroxyalkoxy, mono- or oligoglycoside radicals and where the alkoxy and hydroxyalkoxy groups may be branched and unbranched and can have 1 to 18 C atoms. Formula (II) denotes, Z5 is a mono- or the oligoglycoside radical, where bonded to this glycoside radical, in each case via an —O— group, is at least one radical selected from certain benzo molecule.